According to Business Wire, on September 12, 2016, Samsung Bioepis announced that it has added Canada to its growing list of jurisdictions in which it has received regulatory approval for its biosimilar of Amgen’s Enbrel® (etanercept). The biosimilar will be marketed in Canada under the brand Brenzys® as a treatment…